The flavonoid apigenin protects brain neurovascular coupling against amyloid-β25-35-induced toxicity in mice

Journal of Alzheimer's Disease

Volumn 24, Issue 1, 2011, Pages 85-100

  Liu, Rui ^a,b   Zhang, Tiantai ^a,b   Yang, Haiguang ^a,b   Lan, Xi ^a,b   Ying, Jian ^a,b   Du, Guanhua ^a,b  

^a INSTITUTE OF MATERIA MEDICA   (China)

^b BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

Author keywords

Amyloid peptide; apigenin; blood brain barrier; neurovascular unit

Indexed keywords

ACETYLCHOLINE; ACETYLCHOLINESTERASE; AMYLOID BETA PROTEIN[25-35]; APIGENIN; BRAIN DERIVED NEUROTROPHIC FACTOR; BRAIN DERIVED NEUROTROPHIC FACTOR RECEPTOR; CLAUDIN 5; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; LANTHANUM; OCCLUDIN; PHOSPHOPROTEIN; PROTEIN ZO1;

ACETYLCHOLINE BRAIN LEVEL; AMNESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN BLOOD FLOW; BRAIN BLOOD VESSEL; BRAIN CAPILLARY; BRAIN CORTEX; BRAIN NERVE CELL; BRAIN PROTECTION; BRAIN TOXICITY; CELL ULTRASTRUCTURE; CEREBROVASCULAR DISEASE; CHOLINERGIC SYSTEM; CONTROLLED STUDY; DRUG MECHANISM; ENZYME INHIBITION; LEARNING DISORDER; MALE; MAZE TEST; MEMORY DISORDER; MICROVASCULARIZATION; MORPHOLOGY; MOUSE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN MODIFICATION; TASK PERFORMANCE; TIGHT JUNCTION;

EID: 79955674448     PISSN: 13872877     EISSN: None     Source Type: Journal    
DOI: 10.3233/JAD-2010-101593     Document Type: Article

References (98)

1. Arai H, Lee VM, Otvos L, Greenberg BD, Lowery DE, Sharma SK, Schmidt ML, Trojanowski JQ (1990) Defined neurofilament, tau and beta-amyloid precursor protein epi-topes distinguish Alzheimer from non-Alzheimer senile plaques. Proc Natl Acad Sci USA 87, 2249-2253.
2. Coyle JT, Price DL, Delong MR (1983) Alzheimer's disease: a disorder of central cholinergic innervation. Science 219, 1184-1190. (Pubitemid 13160659)
3. Han BH, Zhou ML, Abousaleh F, Brendza RP, Dietrich HH, Koenigsknecht-Talboo J, Cirrito JR, Milner E, Holtzman DM, Zipfel GJ (2008) Cerebrovascular dysfunction in amyloid precursor protein transgenic mice: contribution of soluble and insoluble amyloid-beta peptide, partial restoration via gamma-secretase inhibition. J Neurosci 28, 13542-13550.
4. Shin HK, Jones PB, Garcia-Alloza M, Borrelli L, Greenberg SM, Bacskai BJ, Frosch MP, Hyman BT, Moskowitz MA, Ayata C (2007) Age-dependent cerebrovascular dysfunction in a transgenic mouse model of cerebral amyloid angiopathy. Brain 130, 2310-2319. (Pubitemid 47327629)
5. Greenberg SM, Rebeck GW, Vonsattel JP, Gomez-Isla T, Hyman BT (1995) Apolipoprotein E epsilon 4 and cerebral hemorrhage associated with amyloid angiopathy. Ann Neurol 38, 254-259.
6. Olichney JM, Hansen LA, Hofstetter CR, Grundman M, Katzman R, Thal LJ (1995) Cerebral infarction in Alzheimer's disease is associated with severe amyloid angiopathy and hypertension. Arch Neurol 52, 702-708.
7. Farkas E, Luiten PG (2001) Cerebral microvascular pathology in aging and Alzheimer's disease. Prog Neurobiol 64, 575-611. (Pubitemid 32304447)
8. Iadecola C (2004) Neurovascular regulation in the normal brain and in Alzheimer's disease. Nat Rev Neurosci 5, 347-360. (Pubitemid 38568496)
9. Zlokovic BV (2008) The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron 57, 178-201.
10. De la Torre J, Mussivand T (1993) Can disturbed brain microcirculation cause Alzheimer's disease? Neurol Res 15, 146-153. (Pubitemid 23166998)
11. De la Torre JC (2004) Is Alzheimer's disease a neurodegen-erative or a vascular disorder? Data, dogma, and dialectics. Lancet Neurol 3, 184-190. (Pubitemid 38232669)
12. Thoenen H (1995) Neurotrophins and neuronal plasticity. Science 270, 593-598.
13. Lewin GR, Barde YA (1996) Physiology ofthe neurotrophins. Annu Rev Neurosci 19, 289-317.
14. Bibel M, Barde YA (2000) Neurotrophins: key regulators of cell fate and cell shape in the vertebrate nervous system. Genes Dev 14, 2919-2937.
15. Chao MV (2003) Neurotrophins and their receptors: a convergence point for many signalling pathways. Nat Rev Neurosci 4, 299-309. (Pubitemid 37271375)
16. Tapia-Arancibia L, Rage F, Givalois L, Arancibia S (2004) Physiology of BDNF: focus on hypothalamic function. Front Neuroendocrinol 25, 77-107. (Pubitemid 39582717)
17. Holsinger RMD, Schnarr J, Henry P, Castelo VT, Fahnestock M (2000) Quantitation of BDNF mRNA in human parietal cortex by competitive reverse transcriptionpolymerase chain reaction: decreased levels in Alzheimer's disease. Mol Brain Res 76, 347-354. (Pubitemid 30179772)
18. Michalski B, Fahnestock M (2003) Pro-brain-derived neurotrophic factor is decreased in parietal cortex in Alzheimer's disease. Mol Brain Res 111, 148-154. (Pubitemid 36332338)
19. Peng S, Wuu J, Mufson EJ, Fahnestock M (2005) Precursor form of brain-derived neurotrophic factor and mature brain-derived neurotrophic factor are decreased in the preclinical stages of Alzheimer's disease. J Neurochem 93, 1412-1421. (Pubitemid 40853264)
20. Laske C, Stransky E, Leyhe T, Eschweiler GW, Maetzler W, Wittorf A, Soekadar S, Richartz E, Koehler N, Bartels M, Buchkremer G, Schott K (2007) BDNF serum and CSF concentrations in Alzheimer's disease, normal pressure hydrocephalus and healthy controls. JPsychiat Res 41, 387-394. (Pubitemid 46187251)
21. Tweedle CD, Modney BK, Hatton GI (1988) Ultrastructural changes in the rat neurohypophysis following castration and testosterone replacement. Brain Res Bull 20, 33-38. (Pubitemid 18048373)
22. Abbott NJ, Ronnback L, Hansson E (2006) Astrocyteendothelial interactions at the blood-brain barrier. Nat Rev Neurosci 7, 41-53.
23. Persidsky Y, Ramirez SH, Haorah J, Kanmogne GD (2006) Blood-brain barrier: structural components and function under physiologic and pathologic conditions. JNeuroimmune Pharmacol 1, 223-236. (Pubitemid 44244128)
24. Wilcock DM, Vitek MP, Colton CA (2009) Vascular amyloid alters astrocytic water and potassium channels in mouse models and humans with Alzheimer's disease. Neuroscience 159, 1055-1069.
25. Del Zoppo GJ (2006) Stroke and neurovascular protection. N Engl J Med 354, 553-555. (Pubitemid 43209102)
26. Duthie G, Crozier A (2000) Plant-derived phenolic antioxidants. Curr Opin Clin Nutr Metab Care 3, 447-451.
27. McVean M, Weinberg WC, Pelling JC (2002) A p21(waf1) independent pathway for inhibitory phosphorylation of cyclin-dependent kinase p34(cdc2) and concomitant G(2)/M arrest by the chemopreventive flavonoid apigenin. Mol Carcinog 33, 36-43. (Pubitemid 34052305)
28. Wang IK, Lin-Shiau SY, Lin JK (1999) Induction of apoptosis by apigenin and related flavonoids through cytochrome c release and activation of caspase-9 and caspase-3 in leukaemia HL-60 cells. Eur J Cancer 35, 1517-1525.
29. Vargo MA, Voss OH, Poustka F, Cardounel AJ, Grotewold E, Doseff AI (2006) Apigenin-induced-apoptosis is mediated by the activation of PKCδ and caspases in leukemia cells. Biochem Pharmacol 72, 681-692. (Pubitemid 44233544)
30. Fotsis T, Pepper MS, Aktas E, Breit S, Rasku S, Adlercreutz H, Wähälä K, Montesano R, Schweigerer L (1997) Flavonoids, dietary-derived inhibitors of cell proliferation and in vitro angiogenesis. Cancer Res 57, 2916-2921. (Pubitemid 27315039)
31. Yin F, Giuliano AE, Law RE, Van Herle AJ (2001) Api-genin inhibits growth and induces G2/M arrest by modulating cyclin-CDK regulators and ERK MAP kinase activation in breast carcinoma cells. Anticancer Res 21, 413-420. (Pubitemid 32267675)
32. Chen D, Daniel KG, Chen MS, Kuhn DJ, Landis-Piwowar KR, Dou QP (2005) Dietary flavonoids as proteasome inhibitors and apoptosis inducers in human leukemia cells. Biochem Pharmacol 69, 1421-1432. (Pubitemid 40602442)
33. Raso GM, Meli R, Di Carlo G, Pacilio M, Di Carlo R (2001) Inhibition of inducible nitric oxide synthase and cyclooxygenase-2 expression by flavonoids in macrophage J774A.1. Life Sci 68, 921-931. (Pubitemid 32168067)
34. Van Dross RT, Hong X, Pelling JC (2005) Inhibition of TPA-induced cyclooxygenase-2 (COX-2) expression by apigenin through downregulation of Akt signal transduction in human keratinocytes. Mol Carcinog 44, 83-91. (Pubitemid 41397173)
35. Hastak K, Gupta S, Ahmad N, Agarwal MK, Agarwal ML, Mukhtar H (2003) Role of p53 and NF-kappaB in epigallocatechin-3-gallate-induced apoptosis of LNCaP cells. Oncogene 22, 4851-4859. (Pubitemid 36981273)
36. Woodman OL, Chan E (2004) Vascular and anti-oxidant actions of flavonols and flavones. Clin Exp Pharmacol Physiol 31, 786-790. (Pubitemid 39556854)
37. Olszanecki R, Gebska A, Kozlovski VI, Gryglewski RJ (2002) Flavonoids and nitric oxide synthase. J Physiol Pharmacol 53, 571-584. (Pubitemid 36014803)
38. Zhang YH, Park YS, Kim TJ, Fang LH, Ahn HY, Hong JT, Kim Y, Lee CK, Yun YP (2000) Endothelium-dependent vasorelaxant and antiproliferative effects of apigenin. Gen Pharmacol 35, 341-347. (Pubitemid 34258517)
39. Guerrero JA, Lozano ML, Castillo J, Benavente-Garcia O, Vicente V, Rivera J (2005) Flavonoids inhibit platelet function through binding to the thromboxane A2 receptor. J Thromb Haemost 3, 369-376. (Pubitemid 41623628)
40. Kang SS, Lee JY, Choi YK, Kim GS, Han BH (2004) Neuro-protective effects of flavones on hydrogen peroxide-induced apoptosis in SH-SY5Y neuroblostoma cells. Bioorg Med Chem Lett 14, 2261-2264. (Pubitemid 38481402)
41. Laursen SE, Belknap JK (1986) Intracerebroventricular injections in mice. Some methodological refinements. JPhar-macol Methods 16, 355-357. (Pubitemid 17189961)
42. Murakami Y, Zhao Q, Harada K, Tohda M, Watanabe H, Matsumoto K (2005) Chotosan, a Kampo formula, improves chronic cerebral hypoperfusion-induced spatial learning deficit via stimulation of muscarinic M1 receptor. Pharmacol Biochem Behav 81, 616-625. (Pubitemid 40966810)
43. Song L, Che W, Min-Wei W, Murakami Y, Matsumoto K (2006) Impairment of the spatial learning and memory induced by learned helplessness and chronic mild stress. Pharmacol Biochem Behav 83, 186-193.
44. Steinmeier R, Bondar I, Bauhuf C, Fahlbusch R (2002) Laser Doppler flowmetry mapping of cerebrocortical microflow: characteristics and limitations. Neuroimage 15, 107-119. (Pubitemid 34852210)
45. Rapôso C, Zago GM, da Silva GH, da Cruz Höfling MA (2007) Acute blood-brain barrier permeabilization in rats after systemic Phoneutria nigriventer venom. Brain Res 1149, 18-29.
46. Sheikov N, McDannold N, Sharma S, Hynynen K (2008) Effect of focused ultrasound applied with an ultrasound contrast agent on the tight junctional integrity of the brain microvascular endothelium. Ultrasound Med Biol 34, 1093-1104. (Pubitemid 351893156)
47. Kim GW, Lewén A, Copin J, Watson BD, Chan PH (2001) The cytosolic antioxidant, copper/zinc superoxide dismutase, attenuates blood-brain barrier disruption and oxidative cellular injury after photothrombotic cortical ischemia in mice. Neuroscience 105, 1007-1018. (Pubitemid 32786813)
48. Ellman GL, Courtney KD, Andres V Jr, Feather-Stone RM (1961) A new and rapid colorimetric determination of acetyl-cholinesterase activity. Biochem Pharmacol 7, 88-95.
49. Arancibia S, Lecomte A, Rage F, Silhol M, Aliaga E, Tapia Arancibia L (2007) In vivo BDNF release and TrkB recep-tors expression in the supraoptic nucleus after osmotic stress stimulus in rats. Neuroscience 146, 864-873. (Pubitemid 46617056)
50. Pedersen WA, Kloczewiak MA, Blusztajn JK (1996) Amy-loid β-protein reduces acetylcholine synthesis in a cell line derived from cholinergic neurons of the basal forebrain. Proc Natl Acad Sci USA 93, 8068-8071. (Pubitemid 26277166)
51. Nitta A, Itoh A, Hasegawa T, Nabeshima T (1994) β-Amyloid protein-induced Alzheimer's disease animal model. Neurosci Lett 170, 63-66.
52. Hoshi M, Takashima A, Murayama M, Yasutake K, Yoshida N, Ishiguro K, Hoshino T, Imahori K (1997) Nontoxic amy-loid β peptide 1-42 suppresses acetylcholine synthesis. J Biol Chem 272, 2038-2041.
53. Kar S, Issa AM, Seto D, Auld DS, Collier B, Quirion R(1998) Amyloid β-peptide inhibits high-affinity choline uptake and acetylcholine release in rat hippocampal slices. J Neurochem 70, 2179-2187. (Pubitemid 28207844)
54. Sigurdsson EM, Lee JM, Dong XW, Hejna MJ, Lorens SA (1997) Bilateral injections of amyloid-β 25-35 into the amyg-dala of young Fischer rats: behavioral, neurochemical, and time dependent histopathological effects. Neurobiol Aging 18, 591-608. (Pubitemid 28046412)
55. Pavia J, Alberch J, Alverez I, Toledano A, de Ceballos ML (2000) Repeated intracerebroventricular administration of β-amyloid 25-35 to rats decreases muscarinic receptors in cerebral cortex. Neurosci Lett 278, 69-72. (Pubitemid 30009899)
56. Nakdook W, Khongsombat O, Taepavarapruk P, Taepavarapruk N, Ingkaninan K (2010) The effects of Tabernaemontana divaricata root extract on amyloid beta-peptide 25-35 peptides induced cognitive deficits in mice. J Ethnopharmacol 130, 122-126.
57. Rovira C, Arbez N, Mariani J (2002) Aβ(25-35) and Aβ(1-40) act on different calcium channels in CA1 hippocampal neu-rons. Biochem Biophys Res Commun 296, 1317-1321.
58. Gruden MA, Davidova TB, Malisauskas M, Sewell RD, Voskresenskaya NI, Wilhelm K, Elistratova EI, Sherstnev VV, Morozova-Roche LA (2007) Differential neuroimmune markers to the onset of Alzheimer's disease neuro-degeneration and dementia: autoantibodies to Abeta(25-35) oligomers. S100b and neurotransmitters. J Neuroimmunol 186, 181-192. (Pubitemid 46773048)
59. Zhang L, Yu H, Zhao X, Lin X, Tan C, Cao G, Wang Z (2010) Neuroprotective effects of salidroside against beta-amyloid-induced oxidative stress in SH-SY5Y human neuroblastoma cells. Neurochem Int 57, 547-555.
60. Harkany T, O'Mahony S, Kelly JP, Soós K, Törõ I, Penke B, Luiten PG, Nyakas C, Gulya K, Leonard BE (1998) Beta-amyloid(Phe(SO3H)24)25- 35 in rat nucleus basalis induces behavioral dysfunctions, impairs learning and memory and disrupts cortical cholinergic innervation. Behav Brain Res 90, 133-145. (Pubitemid 28080555)
61. Yamaguchi Y, Kawashimar S (2001) Effects of amyloid-beta-(25-35) on passive avoidance, radial-arm maze learning and choline acetyltransferase activity in the rat. Eur J Pharmacol 412, 265-272. (Pubitemid 32144942)
62. Maurice T, Lockhart BP, Privat A (1996) Amnesia induced in mice by centrally administered β-amyloid peptides involves cholinergic dysfunction. Brain Res 706, 181-193. (Pubitemid 26048681)
63. Yankner BA, Duffy LK, Kirschner DA (1990) Neurotrophic and neurotoxic effects of amyloid β-protein: reversal by tachykinin neuropeptides. Science 250, 279-282.
64. Pike CJ, Walencewicz AJ, Glabe CG, Cotman CW (1991) In vitro aging of β-amyloid protein causes peptide aggregation and neurotoxicity. Brain Res 563, 311-314.
65. Pike CJ, Burdick D, Walencewicz AJ, Glabe CG, Cotman CW (1993) Neurodegeneration induced by β-amyloid peptides in vitro: the role of peptide assembly state. J Neurosci 13, 1676-1687. (Pubitemid 23095409)
66. Cotman CW, Anderson AJ (1995) A potential role for apop-tosis in neurodegeneration and Alzheimer's disease. Mol Neurobiol 10, 19-45.
67. Hartley DM, Walsh DM, Ye CP, Diehl T, Vasquez S, Vassilev PM, Teplow DB, Selkoe DJ (1999) Protofibrillar intermediate induce acute electrophysiological changes and progressive neurotoxicity in cortical neurons. J Neurosci 19, 8876-8884. (Pubitemid 30226709)
68. Lambert MP, Barlow AK, Chromy BA, Edwards C, Freed R, Liosatos M, Morgan TE, Rosovsky I, Trommer B, Voila KL, Wals P, Zhang C, Finch CE, Krafft GA, Klein WL (1998) Dif-fusible, nonfibrillar ligands derived from Aβ1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci US A 95, 6448-6453.
69. Finkel T, Holbrook NJ (2000) Oxidants, oxidative stress and the biology of ageing. Nature 408, 239-247.
70. Snyder EM, Nong Y, Almeida CG, Paul S, Moran T, Choi EY, Nairn AC, Salter MW, Lombroso PJ, Gouras GK, Greengard P (2005) Regulation of NMDA receptor trafficking by amyloid-beta. Nat Neurosci 8, 1051-1058. (Pubitemid 41061516)
71. Harkany T, De Jong GI, Soo's K, Penke B, Luiten PG, Gulya K (1995) Betaamyloid (1-42) affects cholinergic but not parvalbumin-containing neurons in the septal complex of the rat. Brain Res 698, 270-274.
72. Harkany T, Lengyel Z, Soo's K, Penke B, Luiten PG, Gulya K (1995) Cholinotoxic effects of beta-amyloid (1-42) peptide on cortical projections ofthe rat nucleus basalis magnocellularis. Brain Res 695, 71-75.
73. Boncristiano S, Calhoun ME, Kelly PH, Pfeifer M, Bondolfi L, Stalder M, Phinney AL, Abramowski D, Sturchler-Pierrat C, Enz, Sommer B, Staufenbiel M, Jucker M (2002) Choliner-gic changes in the APP23 transgenic mouse model of cerebral amyloidosis. J Neurosci 22, 3234-3243. (Pubitemid 35379210)
74. Kelly JF, Furukawa K, Barger SW, Rengen MR, Mark RJ, Blanc EM, Roth GS, Mattson MP (1996) Amyloid beta-peptide disrupts carbachol-induced muscarinic cholinergic signal transduction in cortical neurons. Proc Natl Acad Sci USA 93, 6753-6758.
75. Mattson MP, Magnus T (2006) Ageing and neuronal vulner-ability. Nat Rev Neurosci 7, 278-294.
76. Salehi A, Delcroix JD, Mobley WC (2003) Traffic at the intersection of neurotrophic factor signaling and neurodegen-eration. Trends Neurosci 26, 73-80. (Pubitemid 36110541)
77. Echeverria V, Berman DE, Arancio O (2007) Oligomers of beta-amyloid peptide inhibit BDNF-induced arc expression in cultured cortical neurons. Curr Alzheimer Res 4, 518-521. (Pubitemid 350248384)
78. Wang DC, Chen SS, Lee YC, Chen TJ (2006) Amyloid-[beta] at sublethal level impairs BDNF-induced arc expression in cortical neurons. Neurosci Lett 398, 78-82.
79. Tong L, Balazs R, Thornton PL, Cotman CW (2004) Beta-amyloid peptide at sublethal concentrations downregulates brain-derived neurotrophic factor functions in cultured corti-cal neurons. J Neurosci 24, 6799-6809. (Pubitemid 38993902)
80. Tyler WJ, Alonso M, Bramham CR, Pozzo-Miller LD (2002) From acquisition to consolidation: on the role of brain-derived neurotrophic factor signaling in hippocampaldependent learning. Learn Mem 9, 224-237.
81. Heldt SA, Stanek L, Chhatwal JP, Ressler KJ (2007) Hippocampus-specific deletion of BDNF in adult mice impairs spatial memory and extinction of aversive memories. Mol Psychiatry 12, 656-670. (Pubitemid 46998249)
82. Bekinschtein P, Cammarota M, Igaz LM, Bevilaqua LR, Izquierdo I, Medina JH (2007) Persistence of long-term memory storage requires a late protein synthesis-and BDNF-dependent phase in the hippocampus. Neuron 53, 261-277. (Pubitemid 46074403)
83. Bechmann I, Galea I, Perry VH (2007) What is the blood-brain barrier (not)? Trends Immunol 28, 5-11. (Pubitemid 46001619)
84. Hawkins BT, Davis TP (2005) The blood-brain barrier/neurovascular unit in health and disease. Pharmacol Rev 57, 173-185. (Pubitemid 41043883)
85. Su GC, Arendash GW, Kalaria RN, Bjugstad KB, Mullan M (1999) Intravascular infusions of soluble beta-amyloid compromise the blood-brain barrier, activate CNS glial cells and induce peripheral hemorrhage. Brain Res 818, 105-117. (Pubitemid 29227289)
86. Ujiie M, Dickstein DL, Carlow DA, Jefferies WA (2003) Blood-brain barrier permeability precedes senile plaque formation in an Alzheimer disease model. Microcirculation 10, 463-470. (Pubitemid 39004272)
87. Stewart PA, Hayakawa K, Akers MA, Vinters HV (1992) A morphometric study of the blood-brain barrier in Alzheimer's disease. Lab Invest 67, 734-742. (Pubitemid 23024623)
88. Takechi R, Galloway S, Pallebage-Gamarallage MM, Mamo JC (2008) Chylomicron amyloid-beta in the aetiology of Alzheimer's disease. Atherosclerosis 9, 19-25.
89. Lovell MA, Markesbery WR (2006) Amyloid beta peptide, 4-hydroxynonenal and apoptosis. Curr Alzheimer Res 3, 359-364. (Pubitemid 44351479)
90. Ko FN, Huang TF, Teng CM (1991) Vasodilatory action mechanisms of apigenin isolated from Apium graveolens in rat thoracic aorta. Biochim Biophys Acta 1115, 69-74.
91. Stamatovic SM, Dimitrijevic OB, Keep RF, Andjelkovic AV (2006) Protein kinase Calpha-RhoA cross-talk in CCL2-induced alterations in brain endothelial permeability. J Biol Chem 281, 8379-8388. (Pubitemid 43847939)
92. Ishizaki T, Chiba H, Kojima T, Fujibe M, Soma T, Miyajima H, Nagasawa K, Wada I, Sawada N (2003) Cyclic AMP induces phosphorylation of claudin-5 immunoprecipitates and expression of claudin-5 gene in blood-brain-barrier endothelial cells via protein kinase A-dependent and-independent pathways. Exp Cell Res 290, 275-288. (Pubitemid 37272172)
93. Duarte J, Pérez Vizcaíno F, Utrilla P, Jiménez J, Tamargo J, Zarzuelo A (1993) Vasodilatory effects of flavonoids in rat aortic smooth muscle. Structure-activity relationships. Gen Pharmacol 24, 857-862. (Pubitemid 23231766)
94. Wolburg H, Lippoldt A (2002) Tight junctions of the bloodbrain barrier: development, composition and regulation. Vascul Pharmacol 38, 323-337. (Pubitemid 36398254)
95. Zehendner CM, Luhmann HJ, Kuhlmann CR (2009) Studying the neurovascular unit: an improved blood-brain barrier model. J Cereb Blood Flow Metab 29, 1879-1884.
96. Roman GC, Kalaria RN (2006) Vascular determinants of cholinergic deficits in Alzheimer disease and vascular dementia. Neurobiol Aging 27, 1769-1785. (Pubitemid 44572575)
97. Sato A, Sato Y, Uchida S (2002) Regulation of cerebral cortical blood flow by the basal forebrain cholinergic fibers and aging. Auton Neurosci 96, 13-19. (Pubitemid 34158550)
98. Whitehouse PJ (2004) Paying attention to acetylcholine: the key to wisdom and quality of life? Prog Brain Res 145, 311-317. (Pubitemid 37442952)